Move marks commitment to leading the frontier of AI-driven innovation and simulation in life sciences, company says.
InSilicoTrials revealed that it has officially hired Mark Lovern to be its new chief platform officer. In his new role, Lovern will focus on combining his scientific knowledge with artificial intelligence (AI), machine learning (ML) and simulation technologies, along with an in-depth understanding of regulatory science, to drive the development of the InSilicoTrials.com platform and position it as a catalyst for hyper-accelerating life science R&D.
"Mark's extensive experience and mastery in model-informed drug development align seamlessly with our vision of revolutionizing the life sciences industry," said Luca Emili, CEO, InSilicoTrials, in a company press release. "His prior achievements, combined with our groundbreaking AI and simulations platform, will surely take our capabilities to unprecedented heights.”
Reference: Mark Lovern Joins InSilicoTrials as Chief Platform Officer. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/mark-lovern-joins-insilicotrials-as-chief-platform-officer-301958909.html
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.